The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.

Performance in Q1 was impacted by a deliberate, large-scale commercial expansion that disrupted 40% of sales territories through simultaneous changes in representative-to-physician and representative-to-manager relationships.

Management attributes the revenue dip to transition costs, including representative onboarding, extensive training time out of the field, and the rebuilding of account relationships within realigned territories.

The 60% of territories where relationships remained intact performed in line with expectations, which management cites as evidence that underlying demand and market fundamentals remain strong.

The company published a landmark real-world evidence study of 603 PEDD patients, demonstrating that the technology reduces health care utilization and generates approximately $7.7 thousand in per-patient cost avoidance.

Clinical data showed PEDD preserved immune function by nearly eliminating lymphopenia at high-adopter centers, a critical factor for maintaining patient eligibility for downstream immunotherapy.

Strategic expansion into new applications—including uterine, thyroid, and genicular artery embolization—addresses a combined $2.5 billion US market opportunity beyond the core liver business.

Full-year 2026 revenue guidance was revised to $54 million to $57 million, reflecting Q1 expansion disruption and a 5-month delay in FDA clearance for TriNav Advance.

The TriNav Advance launch is now expected in the second half of 2026, with guidance assuming a prudent market evaluation period following the delayed clearance.

Management expects steady, month-over-month sales productivity improvements throughout the remainder of the year as the newly doubled sales force completes its 6- to 9-month ramp period.

The PERIO-1 readout for nalotolimod remains on track for 2026, with the company intending to advance its pancreatic programs through a partnership structure to preserve capital.

Upcoming clinical catalysts include the submission of results from the TETHER and TRI-FI 90 studies for publication in the second quarter.

FDA review of TriNav Advance is currently running 5 months past the 30-day MDUFA goal, creating uncertainty around the exact timing of second-half revenue contributions.

The company successfully raised growth capital in Q1, which funded the commercial build-out but also contributed to higher non-cash stock-based compensation expenses.

Territory realignment was necessary because previous sales footprints had expanded beyond the capacity of individual representatives to cover effectively.

Management flagged that Q1 G&A expenses are seasonally higher due to annual public company costs materializing in the first quarter.

One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.

Management noted that the 60% of territories not disrupted by the expansion serve as a 'control group' confirming steady demand.

The sales organization is now largely in place, and management expects a continuous ramp in productivity as new hires exit the training phase.

The company more than doubled the number of territories and added executive-level management to engage directly with hospital systems and payers.

The expansion was slightly larger than originally planned due to the high caliber of talent attracted following the Q1 capital raise.

Management anticipates marginal sequential revenue gains in Q2 as representatives complete training.

Meaningful revenue step-ups are projected for Q3 and Q4 as the expanded capacity reaches full productivity.

The data validates PEDD as a therapeutic delivery platform rather than just a device, showing improved tumor targeting with less off-target toxicity.

Management believes the evidence of preserved immune function will resonate strongly with the oncology community, potentially making PEDD a standard of care for combination therapies.